Why Tenet, CVS, Thermo Fisher And Sarepta Are Moving Today

Tenet Healthcare THC shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $27 to $60.

Tenet is a Dallas-based healthcare provider organization operating a collection of hospitals (65) and many outpatient facilities, including ambulatory surgery centers, urgent care centers, freestanding imaging centers, freestanding emergency rooms/micro-hospitals, and physician practices across the United States.

Tenet Healthcare shares were trading up 2.82% at $46. The stock has a 52-week high of $48.11 and a 52-week low of $10.

CVS Health CVS shares are trading higher after Jefferies upgraded the stock from Hold to Buy and announced a $90 price target.

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing about 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S.

CVS Health shares were trading up 1.91% at $75.40. The stock has a 52-week high of $76.44 and a 52-week low of $52.04.

Thermo Fisher Scientific TMO shares are trading higher after Credit Suisse upgraded the stock from Neutral to Outperform and raised its price target from $490 to $556 per share.

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents.

Thermo Fisher Scientific shares were trading up 1.86% at $509.76. The stock has a 52-week high of $532.57 and a 52-week low of $250.21.

Sarepta Therapeutics SRPT shares are trading lower after the company reported its 102 Study Evaluating its SRP-9001 did not achieve statistical significance on the primary functional endpoint of improvement in NSAA total score compared to Placebo at 48 weeks.

Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates.

Sarepta Therapeutics shares were trading down 50.58% at $83.49. The stock has a 52-week high of $181.83 and a 52-week low of $78.06.